hptn research

 

hptn research

 

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-network review process that ensures compliance with current ethical guidelines and regulatory procedures.

Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites. The CORE Protocol Contact can provide additional information and materials.

Recent Publications

Sandfort TGM, Kreniske P, Mbeda C, Reynolds D, Tshabalala G, Madiwati B, Ogendo A, Dominquez K, Panchia R, Gondwe D, Hamilton EL, Guo X, Cummings V . Interest in I-PrEP and Willingness to Participate in Clinical Trials Among Men and Transfeminine Persons Who have Sex with Men in Sub-Saharan Africa: Quantitative and Qualitative Findings from HPTN 075. AIDS Behav. 2024, 2361-2377
Beauchamp G, Hosek S, Donnell D, Chan KCG, Anderson PL, Dye BJ, Mgodi N, Bekker LG, Delany-Moretlwe S, Celum C; HPTN 082 study team . The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082. AIDS Behav. 2024, 5: 1512-1521
Meyer D, Lowensen K, Perrin N, et al, Diane Meyer ,Kelly Lowensen,Nancy Perrin,Ayana Moore,Shruti H. Mehta,Cheryl R. Himmelfarb,Thomas V. Inglesby,Jacky M. Jennings,Alexandra K. Mueller,Jessica N. LaRicci,Woudase Gallo,Adam P. Bocek,Jason E. Farley . An evaluation of the impact of social and structural determinants of health on forgone care during the COVID-19 pandemic in Baltimore, Maryland. PLoS One. 2024
Sobieszczyk ME, Mannheimer S, Paez CA, Yu C, Gamble T, Theodore DA, Chege W, Yacavone M, Hanscom B, Heptinstall J, Seaton KE, Zhang L, Miner MD, Eaton A, Weiner J, Mayer K, Kalams S, Stephenson K, Julg B, Caskey M, Nussenzweig M, Gama L, Barouch DH, Ackerman ME, Tomaras G, Huang Y, Montefiori D . Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults. Lancet HIV. 2023, 10: e653-e662.
Donnell D, Gao F, Hughes JP, Hanscom B, Corey L, Cohen MS, Edupuganti S, Mgodi N, Rees H, Baeten JM, Gray G, Bekker LG, Hosseinipour M, Delany-Moretlwe S . Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.. J Int AIDS Soc. 2023, 26

Scholars Program

The HIV Prevention Trials Network (HPTN) is proud to offer two scholarship programs for early-career investigators funded through a supplement from the National Institute of Allergy and Infectious Diseases (NIAID). The HPTN Scholars Program now includes two components: a domestic (U.S.) program and an international program. Both programs seek to increase opportunities for scientists from groups under-represented in HIV prevention research.

In the domestic program, successful applicants will be Investigators who have received their terminal degree (MD, Phd, etc). For the international version, current MD, PhD, and MBChB students may apply, along with individuals having already graduated with their terminal degree. In both programs, applicants should desire to work with a mentor scientist in the Network to complete a research project based upon an existing HPTN research study.

Learn more about the Scholars Program

Meet the Scholars

Publications and Posters